Global biotechnology company and specialists in microbial solutions Novozymes has struck a deal with German-based researchers Organobalance. Although Novozymes is not revealing financial details of the acquisition, it says the deal will complement the company’s existing platform with applications across industries.
Organobalance GmbH specializes in microbial screening, assay technology and developing natural microbial solutions for food industry partners. It owns a large collection of microbial strains, some dating back to the 1920s, and has expertise in screening and metabolic engineering for new product developments for food applications.
The company works on improving shelf life, protection from microbial contamination, infections, pathogenic bacteria, clean label solutions by replacing undesirable ingredients and using natural alternatives as well as the economic production of these natural ingredients for improved texture, flavor, color and stability.
“The experience of Organobalance’s founding scientists, and the company’s know-how, immediately strengthen Novozymes’ existing capabilities within microbial technologies,” says Sebastian Soderberg, vice president for new business development, incubation & acquisitions at Novozymes. “Organobalance will advance our understanding to develop new, sustainable solutions across industries, and provide us with additional commercial opportunities.”
Organobalance will be integrated into Novozymes’ global organization but will continue to be based in Germany so as to benefit from the established biotechnology capabilities of the country’s capital region and the company’s strong ties to German academia, innovation environments, and markets.
“Organobalance and Novozymes possess similar ambitions and company cultures,” adds Soderberg.
Source: Food Ingredients First
Trinseo (NYSE: TSE), a specialty material solutions provider, announced it has initiated an information and consultation process with the Works Council of Trinseo Deutschland GmbH regarding the potential closure of its styrene monomer production site in Boehlen, Germany.
H.B. Fuller Company announced that Celeste Mastin, Executive Vice President and Chief Operating Officer, will succeed Jim Owens as H.B. Fuller’s President and Chief Executive Officer, effective December 4, 2022. Upon assuming the role, Mastin will also join the Company’s Board of Directors, replacing Owens, who will be retiring.
New LyondellBasell CEO Peter Vanacker, who joined the company from Neste in May, today named his senior executive team and outlined organizational changes, including creation of a circular and low-carbon solutions business. All changes will be effective 1 October.